StocktoriaCuranex Pharmaceuticals Inc CURX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| Financials | ||
| Operating income | -$4.2M | -$365,062 |
| Net income | -$4.2M | -$361,506 |
| Operating cash flow | -$10.5M | -$555,575 |
| Total assets | $11.6M | $517,935 |
| Total liabilities | $361,040 | $14,575 |
| Shareholders' equity | $11.2M | $503,360 |
| Ratios | ||
| Return on assets | -36.5% | -69.8% |
| Return on equity | -37.7% | -71.8% |
| Current ratio | 81.93 | 35.54 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0002025942 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.